Amanta Healthcare Limited has provided a web-link for accessing its Integrated Annual Report and the notice for the 31st Annual General Meeting (AGM) for FY26. The company sent this communication on August 24, 2026, to shareholders who have not registered their email addresses with the company, Registrar and Share Transfer Agent (RTA), or Depository Participants.

The 31st AGM is scheduled for Wednesday, September 16, 2026, at 12:00 pm. It will be conducted through video conferencing or other audio-visual means. The notice and annual report are available electronically to members with registered emails and can be accessed via the company website at www.amanta.co.in under the path /annual-report.

E-Voting Schedule

Shareholders can cast their votes remotely during a specified window before the meeting. Those who vote remotely cannot vote again during the live session.

Members acquiring shares after the notice dispatch but appearing in the register as of the cut-off date can exercise voting rights. The electronic voting system is provided by Central Depository Services (India) Limited.

Compliance Details

The meeting follows the Ministry of Corporate Affairs General Circular No. 03/2025 dated September 22, 2025, and General Circular No. 20/2020 dated May 5, 2020. Nikhita Dinodia, Company Secretary and Compliance Officer, confirmed the arrangements.

The company also reminded physical shareholders to update KYC details pursuant to SEBI Master Circular No. SEBI/HO/MIRSD/POD-1/P/CIR/2024/37 dated May 7, 2024. This includes recording PAN, address, mobile number, bank account details, specimen signature, and nomination choice. Shareholders holding securities in physical mode without updated details will only be eligible for payments via electronic mode from April 1, 2024.

Amanta Healthcare Limited reported a resilient financial performance for the quarter ended June 30, 2026, with revenue from operations rising by approximately 5% year-on-year to ₹69 crore. Despite facing inflationary pressures and a temporary spike in polymer raw material costs driven by geopolitical tensions, the company maintained a healthy EBITDA margin of roughly 22%, translating to an EBITDA of about ₹15 crore. The stable profitability underscores the effectiveness of management’s operational discipline and price realization strategies during a period characterized by broader business slowdowns.

The primary driver of the current quarter’s cost pressure was not merely raw material volatility but also the absorption of overheads related to upcoming capacity expansions. Bhavesh Patel, Chairman and Managing Director, noted that manpower and other operating costs were incurred in anticipation of the SteriPort Line 3 commissioning, which was delayed by one quarter due to civil construction activities. Consequently, these overheads were absorbed without corresponding revenue contribution from the new line during Q1FY27. Paras Mehta, Chief Financial Officer, added that while polymer prices surged by 70-80% for two months, the impact was mitigated through price corrections, with selling prices increased by approximately ₹1.50 per unit against an input cost rise of ₹2.25.

Capacity Expansion and Timelines

Amanta Healthcare is currently executing significant capacity expansions aimed at enhancing its sterile dosage form portfolio. The SteriPort platform, which contributes around 44% of total revenue, is being expanded from 6.6 crore bottles per year to roughly 12 crore bottles per year. This expansion targets high-value therapies including oncology, critical care, anesthetics, and pediatrics. Although originally targeted for Q1FY27, the commercial production of SteriPort Line 3 has been shifted to the last week of August 2026, following FDA plan approvals on August 5, 2026. Validation and qualification activities are expected to conclude by August 18, 2026.

Simultaneously, the company is advancing its Small Volume Parenteral (SVP) facility, which focuses on export-centric products such as inhalation solutions, ophthalmics, and preservative-free unit doses. The SVP business contributed around 20% of FY26 revenue. Management expects this new facility to commence operations in Q4FY27, specifically between February and March 2027, following Factory Acceptance Testing (FAT) scheduled for November 2026 in the USA. Unlike the SteriPort project, the SVP facility requires minimal civil work, reducing timeline speculation.

Financial Outlook and Margins

Looking ahead, management projects that the full utilization of SteriPort Line 3 will contribute approximately ₹70 crore to the top line over the remaining seven months of FY27. For FY28, with both SteriPort and SVP capacities live, peak revenue potential is estimated at roughly ₹425 crore. EBITDA margins are expected to expand to 25-26% in FY28, driven by operating leverage from the new lines and cost savings from a 10.8 MW captive solar power plant commissioned in June 2026. The solar project is expected to save approximately ₹75 lakh per month, contributing to an overall EBITDA margin expansion of 4-5% when combined with the operational efficiencies of SteriPort Line 3.

Depreciation expenses are set to increase by approximately ₹6 crore annually compared to FY26, due to the new SteriPort line, SVP facility, and solar plant. Interest costs are projected at ₹21 crore for FY27 and ₹18-19 crore for FY28, reflecting a gradual reduction in debt despite additional borrowing for the solar captive project. The effective tax rate is expected to remain at 26%. Working capital days remain elevated at 141 days for FY26, primarily due to mandatory quarantine periods for export shipments, which can extend up to 25-30 days.

Strategic Growth Drivers

Beyond capacity expansion, Amanta Healthcare is strengthening its formulation development capabilities to support its SVP portfolio. A dedicated team of five scientists is working on a pipeline of 20 products, with one inhalation product expected to be commercialized by mid-September 2026. The long-term vision remains focused on sterile dosage forms, with plans to explore new packaging materials beyond plastic, such as glass, and to enter advanced regulated markets in the UK, EU, Australia, and Canada. The incremental Return on Capital Employed (ROCE) for SteriPort Line 3 is estimated at 16-17%, while the SVP facility is projected to yield 14-15% ROCE, positioning the company competitively within the industry.